SE8601644L - ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING - Google Patents

ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING

Info

Publication number
SE8601644L
SE8601644L SE8601644A SE8601644A SE8601644L SE 8601644 L SE8601644 L SE 8601644L SE 8601644 A SE8601644 A SE 8601644A SE 8601644 A SE8601644 A SE 8601644A SE 8601644 L SE8601644 L SE 8601644L
Authority
SE
Sweden
Prior art keywords
human
antibodies
region
antibody preparation
determinants
Prior art date
Application number
SE8601644A
Other languages
Unknown language ( )
Swedish (sv)
Other versions
SE452065B (en
SE8601644D0 (en
Inventor
Ulf R Nilsson
Karl-Erik Svensson
Bo Nilsson
Original Assignee
Ulf R Nilsson
Svensson Karl Erik
Bo Nilsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf R Nilsson, Svensson Karl Erik, Bo Nilsson filed Critical Ulf R Nilsson
Priority to SE8601644A priority Critical patent/SE452065B/en
Publication of SE8601644D0 publication Critical patent/SE8601644D0/en
Priority to AU72868/87A priority patent/AU7286887A/en
Priority to EP19870902799 priority patent/EP0263161A1/en
Priority to JP50252087A priority patent/JPS63503089A/en
Priority to PCT/SE1987/000142 priority patent/WO1987006344A1/en
Publication of SE8601644L publication Critical patent/SE8601644L/en
Publication of SE452065B publication Critical patent/SE452065B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Antibody preparation directed against an individual neoantigen in the C3b region of human C3, and the use and production thereof. The preparation is characterized by immunnochemically reacting with (a) antigenic determinants in the C3b region of the alpha or beta chain of denatured human C3 in which the disulfide bonds have been reduced, but not with (b) human native C3. The use comprises immunochemically binding the preparation to C3 fragments, especially C3 fragments bound to immune complexes. The production encompasses the raising of an immune response containing the antibodies and selecting from said response the antibodies having the specificity given above.
SE8601644A 1986-04-11 1986-04-11 ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING SE452065B (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE8601644A SE452065B (en) 1986-04-11 1986-04-11 ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING
AU72868/87A AU7286887A (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
EP19870902799 EP0263161A1 (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof
JP50252087A JPS63503089A (en) 1986-04-11 1987-03-19 Antibody preparations and uses and production thereof against certain antigenic determinants in human C3
PCT/SE1987/000142 WO1987006344A1 (en) 1986-04-11 1987-03-19 Antibody preparation directed against neoantigens in human c3 (complement factor 3) and the use and manufacture thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8601644A SE452065B (en) 1986-04-11 1986-04-11 ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING

Publications (3)

Publication Number Publication Date
SE8601644D0 SE8601644D0 (en) 1986-04-11
SE8601644L true SE8601644L (en) 1987-10-12
SE452065B SE452065B (en) 1987-11-09

Family

ID=20364149

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8601644A SE452065B (en) 1986-04-11 1986-04-11 ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING

Country Status (5)

Country Link
EP (1) EP0263161A1 (en)
JP (1) JPS63503089A (en)
AU (1) AU7286887A (en)
SE (1) SE452065B (en)
WO (1) WO1987006344A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
CA2400488A1 (en) * 2000-02-08 2001-08-16 The University Of Virginia Patent Foundation Methods for the prevention and treatment of infections using anti-c3b(i) antibodies
US20040224423A1 (en) * 2001-04-30 2004-11-11 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
US7314717B2 (en) 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US6593298B2 (en) * 2001-04-30 2003-07-15 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US20020160434A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1777 daltons
US6602855B2 (en) * 2001-04-30 2003-08-05 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
US6998243B2 (en) 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US20020160532A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons
US7049397B2 (en) * 2001-04-30 2006-05-23 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
WO2005078442A1 (en) * 2004-02-10 2005-08-25 Dantini Daniel C Comprehensive food allergy test
AR069130A1 (en) * 2007-11-02 2009-12-30 Novartis Ag LINK MOLECULES OF THE MAIN COMPLEMENT OPSONIN (C3B) AND METHODS TO MODULATE THE COMPLEMENT COMPONENT
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
WO2011123044A1 (en) * 2010-03-31 2011-10-06 Anamar Ab Method to detect tissue degradation leading to inflammation
ES2564290T3 (en) * 2010-11-02 2016-03-21 Kypha, Inc. Lateral flow immunoassay for complement activation and methods of use for site evaluation of disorders associated with complement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB2117514B (en) * 1982-03-29 1985-08-29 East Anglian Regional Health Polyvalent antiglobulin reagent
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation

Also Published As

Publication number Publication date
SE452065B (en) 1987-11-09
JPS63503089A (en) 1988-11-10
AU7286887A (en) 1987-11-09
WO1987006344A1 (en) 1987-10-22
SE8601644D0 (en) 1986-04-11
EP0263161A1 (en) 1988-04-13

Similar Documents

Publication Publication Date Title
SE8601644L (en) ANTIBODY PREPARATION OUR ANTIBODIES ARE SPECIFIC TO DETERMINANTS IN THE C3 B REGION OF DENATURATED HUMAN C3 AND ITS USE AND MANUFACTURING
EP0597829A4 (en) Novel monoclonal antibody to novel antigen associated with human tumors.
FI930580A (en) TRI-OCH TETRAVALENSISM MONOPECIFIC ANTIGEN BINDANDE PROTEINER
DK0403156T3 (en) Enhanced monoclonal antibodies to the human alpha / beta T cell receptor as well as its preparation and use
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
DE69030494D1 (en) CARCINOMA RELATED HAPTOGLOBIN (HPR)
PH31198A (en) Protein recognized by antibodies raised against native P28 of schitosoma mansoni.
NO175639C (en) Peptide, antibody obtained by the peptide, a method for immunologically determining intact procollagen peptide (type III) and use of the peptide
DE3884646D1 (en) Human carcinoma-associated antigen and antibodies binding to this antigen.
DE58909328D1 (en) Immunogen and its use for the production of antibodies against HbA1c.
ATE230418T1 (en) MONOCLONAL ANTIBODIES AGAINST THE HUMAN MX PROTEIN MXA
EP0460607A3 (en) Novel monoclonal antibody to novel antigen associated with human tumors
ATE72400T1 (en) CROSS-REACTIVE AND PROTECTIVE EPITOPES OF CIRCUMSPOROZOITE PROTEINS.
DE69026875D1 (en) IMMUNE DETERMINATION OF HUMAN OSTEOCALCIN, REAGENT AND SET THEREFOR
NO174153C (en) Antigen and monoclonal antibody for use in vitro, as well as immunological reagents containing them
IT8026986A0 (en) PURIFIED HUMAN PROSTATE ANTIGEN AND PROCEDURE FOR PREPARING ANTIBODY RELATED TO THIS ANTIGEN.
KR890700832A (en) Human monoclonal antibody binding to the antigenic determinant of Gram-negative bacteria
DE3785795D1 (en) MONOCLONAL ANTI-HUMAN CANCER ANTIBODIES.
GB2233091A (en) Immunoassays using monoclonal antibodies directed against natural binding proteins
DK69590D0 (en) HUMAN ANTI-RH (D) MONOCLONAL ANTIBODIES
SE8904007D0 (en) MONOCLONA ANTIBODIES AND DIAGNOSTIZATION METHOD
DK329789D0 (en) MONOCLONAL ANTIBODY
ATE86261T1 (en) TUMOR-ASSOCIATED ANTIGEN.
DE69111429D1 (en) MONOCLONAL ANTIBODIES THAT MAKE A DIFFERENCE BETWEEN NATIVE PROTEINS AND PROTEINS WITH A MODIFIED SEQUENCE.
ATE92081T1 (en) TUMOR-ASSOCIATED ANTIGEN.

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8601644-1

Effective date: 19911108

Format of ref document f/p: F